National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse (NIDA) intends to reissue the notice of funding opportunity (NOFO) RFA-DA-23-026 NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional).
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The NOFO is expected to be published in Spring 2025 with an expected application due date in Fall 2025.
This NOFO will utilize the DP1 activity code. Details of the planned NOFO are provided below.
This Notice encourages investigators with expertise and insights into health equity, health disparities, and/or social determinants of health to begin to consider applying for this NOFO reissue. Early stage investigators and established investigators are both encouraged to consider applying.
The Racial Equity Visionary Award Program supports independent investigators proposing highly innovative research that 1) challenges scientific paradigms that perpetuate inequities, and 2) lays groundwork for large scale efforts to impact substance use-related disparities that affect racial and/or ethnic minority populations in the United States. Supported projects should have the potential to open new areas of research and produce results that may lead to truly novel approaches to substance use prevention, treatment or recovery. The application should reflect an exceptionally creative approach to problem-solving and a long-term commitment to solution-oriented research with racial and/or ethnic minority communities. The research plan must incorporate the perspective of the community. Applications should consider community-engaged research, community-based participatory research, community action research, or related strategies. Principal Investigators are required to commit a minimum of 35% (4.2 person months) of their research effort to the project.
$3,500,000
$700,000 in direct costs
93.279
Applications are not being solicited at this time.
Please direct all inquiries to:
Alexa Romberg, PhD
National Institute on Drug Abuse (NIDA)
alexa.romberg@nih.gov